All In Biotech

Drug Trial Radar · NCT00321620

Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Men With Hormone-refractory Prostate Cancer

A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid (Zometa®) in the Treatment of Bone Metastases in Men With Hormone-Refractory Prostate Cancer

Last checked: Nov 20, 2026Latest source record: Aug 29, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,904 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,904

Actual

Start

Apr 1, 2006

Primary completion

Oct 1, 2009

Study completion Feb 24, 2012

Sponsor

Lead sponsor
AmgenAmgen (AMGN)
Sponsor type
Industry
First posted
May 4, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Supportive care
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine if denosumab is non-inferior to zoledronic acid (Zometa®) in the treatment of bone metastases in men with hormone-refractory prostate cancer

Conditions

  • Bone Metastases

Interventions

  • zoledronic acidDrug

    Q4W 4 mg zoledronic acid IV over minimum 15 minutes and 120 mg denosumab placebo SC

  • denosumabBiological

    Q4W 120 mg denosumab SC and 4 mg zoledronic acid placebo IV over a minimum of 15 minutes

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to the First On-Study SRE (Non-inferiority)Time frame: Up to 40.5 months

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.